Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

[Hungarian clinical application opportunities of PET/MR imaging and first experiences].

Tóth Z, Lukács G, Cselik Z, Bajzik G, Egyed M, Vajda Z, Borbély K, Hadjiev J, Gyarmati T, Emri M, Kovács Á, Repa I.

Orv Hetil. 2018 Aug;159(34):1375-1384. doi: 10.1556/650.2018.31141. Review. Hungarian.

PMID:
30122057
2.

[Pernicious anemia in a thalassemic patient - difficulties of the diagnosis].

Kurdi B, Mezei ZA, Kellner Á, Egyed M.

Orv Hetil. 2018 Aug;159(33):1368-1371. doi: 10.1556/650.2018.31097. Hungarian.

PMID:
30099903
3.

Recommendations for the diagnosis and treatment of patients with polycythaemia vera.

Hatalova A, Schwarz J, Gotic M, Penka M, Hrubisko M, Kusec R, Egyed M, Griesshammer M, Podolak-Dawidziak M, Hellmann A, Klymenko S, Niculescu-Mizil E, Petrides PE, Grosicki S, Sever M, Cantoni N, Thiele J, Wolf D, Gisslinger H.

Eur J Haematol. 2018 Jul 30. doi: 10.1111/ejh.13156. [Epub ahead of print]

PMID:
30058088
4.

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.

Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F.

Ann Hematol. 2018 Sep;97(9):1591-1600. doi: 10.1007/s00277-018-3365-y. Epub 2018 May 27.

5.

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK.

Haematologica. 2018 Nov;103(11):e514-e518. doi: 10.3324/haematol.2018.191361. Epub 2018 May 24. No abstract available.

6.

Evaluation of daily time spent in transportation and traffic-influenced microenvironments by urban Canadians.

Matz CJ, Stieb DM, Egyed M, Brion O, Johnson M.

Air Qual Atmos Health. 2018;11(2):209-220. doi: 10.1007/s11869-017-0532-6. Epub 2017 Nov 30.

7.

Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.

Gángó A, Mózes R, Boha Z, Kajtár B, Timár B, Király PA, Kiss R, Fésüs V, Nagy N, Demeter J, Körösmezey G, Borbényi Z, Marton I, Szőke A, Masszi T, Farkas P, Várkonyi J, Plander M, Pósfai É, Egyed M, Pál K, Radványi G, Hamed A, Csomor J, Matolcsy A, Alpár D, Bödör C.

Leuk Res. 2018 Feb;65:42-48. doi: 10.1016/j.leukres.2017.12.005. Epub 2018 Jan 2.

PMID:
29306106
8.

Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.

Chanan-Khan AA, Zaritskey A, Egyed M, Vokurka S, Semochkin S, Schuh A, Kassis J, Simpson D, Zhang J, Purse B, Foà R.

Lancet Haematol. 2017 Nov;4(11):e534-e543. doi: 10.1016/S2352-3026(17)30168-0. Epub 2017 Sep 25.

PMID:
28958469
9.

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J.

J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20.

PMID:
28930494
10.

[Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the Polycythemia vera patients].

Dombi P, Illés Á, Demeter J, Homor L, Simon Z, Kellner Á, Karádi É, Valasinyószki E, Udvardy M, Egyed M.

Orv Hetil. 2017 Jun;158(23):901-909. doi: 10.1556/650.2017.30766. Hungarian.

PMID:
28580853
11.

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.

Garcia-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, Stauder R, Yee K, Zhu N, Lee JH, Valcarcel D, MacWhannell A, Borbenyi Z, Gazi L, Acharyya S, Ide S, Marker M, Ottmann OG.

Leukemia. 2017 Dec;31(12):2799-2806. doi: 10.1038/leu.2017.159. Epub 2017 May 26.

12.

Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study).

Schneider T, Rosta A, Losonczy H, Radványi G, Ujj G, Egyed M, Illés Á, Jakucs J, Szerafin L, Gasztonyi Z, Masszi T, Iványi J, Demeter J, Dombi P, Tóth A, Borbényi Z.

Pathol Oncol Res. 2018 Apr;24(2):199-205. doi: 10.1007/s12253-017-0234-2. Epub 2017 Apr 21.

PMID:
28432650
13.

Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary.

Király AP, Kállay K, Gángó A, Kellner Á, Egyed M, Szőke A, Kiss R, Vályi-Nagy I, Csomor J, Matolcsy A, Bödör C.

Pathol Oncol Res. 2018 Jan;24(1):83-88. doi: 10.1007/s12253-017-0216-4. Epub 2017 Mar 29.

PMID:
28357685
14.

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.

Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN.

Lancet Haematol. 2017 May;4(5):e225-e236. doi: 10.1016/S2352-3026(17)30027-3. Epub 2017 Mar 20.

PMID:
28336242
15.

[TP53 mutation analysis in chronic lymphocytic leukaemia].

Fésüs V, Marosvári D, Kajtár B, Király PA, Demeter J, Gurbity Pálfi T, Egyed M, Plander M, Farkas P, Mátrai Z, Matolcsy A, Bödör C.

Orv Hetil. 2017 Feb;158(6):220-228. doi: 10.1556/650.2017.30656. Hungarian.

PMID:
28166664
16.

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).

Chanan-Khan A, Egyed M, Robak T, Martinelli de Oliveira FA, Echeveste MA, Dolan S, Desjardins P, Blonski JZ, Mei J, Golany N, Zhang J, Gribben JG.

Leukemia. 2017 May;31(5):1240-1243. doi: 10.1038/leu.2017.47. Epub 2017 Jan 31. No abstract available.

17.

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P.

Lancet Oncol. 2017 Mar;18(3):297-311. doi: 10.1016/S1470-2045(16)30671-4. Epub 2017 Jan 28.

18.

[An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the essential thrombocythaemic patients].

Dombi P, Illés Á, Demeter J, Homor L, Simon Z, Udvardy M, Karádi É, Kellner Á, Egyed M.

Orv Hetil. 2017 Jan;158(3):111-116. doi: 10.1556/650.2017.30638. Hungarian.

PMID:
28110571
19.

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.

Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G.

Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2.

PMID:
27916398
20.

Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.

Dombi P, Illés Á, Demeter J, Homor L, Simon Z, Karadi E, Udvardy M, Egyed M.

Eur J Haematol. 2017 Feb;98(2):106-111. doi: 10.1111/ejh.12806. Epub 2016 Sep 19.

PMID:
27557754
21.

Increased Lipocalin 2 level may have important role in thrombotic events in patients with polycythemia vera and essential thrombocythemia.

Rajnics P, Kellner Á, Karádi É, Moizs M, Bödör C, Király PA, Marosvári D, Andrikovics H, Egyed M.

Leuk Res. 2016 Sep;48:101-6. doi: 10.1016/j.leukres.2016.04.016. Epub 2016 Apr 28.

PMID:
27161323
22.

[Development of the registry for Philadelphia-negative chronic myeloproliferative neoplasia in Hungary].

Dombi P, Illés Á, Demeter J, Homor L, Simon Z, Udvardy M, Egyed M.

Orv Hetil. 2016 Jan 17;157(3):98-103. doi: 10.1556/650.2016.30340. Hungarian.

PMID:
26750731
23.

[Low mean cell hemoglobin is a reliable marker for iron deficiency screening].

Kellner SV, Kellner Á, Haragh A, Dombi P, Karádi É, Rajnics P, Kollár B, Alizadeh H, Ghosh M, Liposits A, Moizs M, Egyed M.

Orv Hetil. 2016 Jan 3;157(1):35-8. doi: 10.1556/650.2016.30328. Hungarian.

PMID:
26708685
24.

Case report: Concomitant Chronic Lymphocytic Leukaemia and Cytogenetically Normal de novo Acute Leukaemia in a Patient.

Kajtár B, Rajnics P, Egyed M, Alizadeh H.

Ann Clin Lab Sci. 2015 Fall;45(5):602-6.

PMID:
26586717
25.

Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.

Krahling T, Balassa K, Kiss KP, Bors A, Batai A, Halm G, Egyed M, Fekete S, Remenyi P, Masszi T, Tordai A, Andrikovics H.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):98-104. doi: 10.1158/1055-9965.EPI-15-0805. Epub 2015 Oct 20.

26.

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.

Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B.

J Clin Oncol. 2015 Apr 10;33(11):1252-7. doi: 10.1200/JCO.2014.57.0952. Epub 2015 Mar 2.

PMID:
25732165
27.

[Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].

Krähling T, Balassa K, Meggyesi N, Bors A, Csomor J, Bátai Á, Halm G, Egyed M, Fekete S, Reményi P, Masszi T, Tordai A, Andrikovics H.

Orv Hetil. 2014 Dec 28;155(52):2074-81. doi: 10.1556/OH.2014.30051. Hungarian.

PMID:
25528320
28.

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.

Andrikovics H, Krahling T, Balassa K, Halm G, Bors A, Koszarska M, Batai A, Dolgos J, Csomor J, Egyed M, Sipos A, Remenyi P, Tordai A, Masszi T.

Haematologica. 2014 Jul;99(7):1184-90. doi: 10.3324/haematol.2014.107482. Epub 2014 Jun 3.

29.

[A simple algorithm for anemia].

Egyed M.

Orv Hetil. 2014 Mar 9;155(10):376-82. doi: 10.1556/OH.2014.29806. Review. Hungarian.

PMID:
24583558
30.

Effects of age, season, gender and urban-rural status on time-activity: CanadianHuman Activity Pattern Survey 2 (CHAPS 2).

Matz CJ, Stieb DM, Davis K, Egyed M, Rose A, Chou B, Brion O.

Int J Environ Res Public Health. 2014 Feb 19;11(2):2108-24. doi: 10.3390/ijerph110202108.

31.

Human health impacts of biodiesel use in on-road heavy duty diesel vehicles in Canada.

Rouleau M, Egyed M, Taylor B, Chen J, Samaali M, Davignon D, Morneau G.

Environ Sci Technol. 2013 Nov 19;47(22):13113-21. doi: 10.1021/es4023859. Epub 2013 Nov 8.

PMID:
24143909
32.

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N.

J Clin Oncol. 2010 Oct 20;28(30):4635-41. doi: 10.1200/JCO.2010.28.1238. Epub 2010 Sep 7.

PMID:
20823423
33.

JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia.

Andrikovics H, Nahajevszky S, Koszarska M, Meggyesi N, Bors A, Halm G, Lueff S, Lovas N, Matrai Z, Csomor J, Rasonyi R, Egyed M, Varkonyi J, Mikala G, Sipos A, Kozma A, Adam E, Fekete S, Masszi T, Tordai A.

Leukemia. 2010 Oct;24(10):1809-13. doi: 10.1038/leu.2010.172. Epub 2010 Sep 2. No abstract available.

PMID:
20811399
34.

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.

Ludwig H, Adam Z, Tóthová E, Hajek R, Labar B, Egyed M, Spicka I, Gisslinger H, Drach J, Kuhn I, Hinke A, Zojer N.

Haematologica. 2010 Sep;95(9):1548-54. doi: 10.3324/haematol.2009.020586. Epub 2010 Apr 23.

35.

[Primary gastrointestinal non-Hodgkin's lymphoma in two Hungarian regions].

Kollár B, Rajnics P, Hunyady B, Zeleznik E, Jakucs J, Egyed M.

Orv Hetil. 2009 Aug 30;150(35):1649-53. doi: 10.1556/OH.2009.28692. Hungarian.

PMID:
19692309
36.

Rare primary extranodal lymphomas: diffuse large B-cell lymphomas of the genital tract.

Rajnics P, Demeter J, Csomor J, Krenács L, Pajor L, Kollár B, Kertész Z, Egyed M.

Ann Hematol. 2009 Dec;88(12):1223-8. doi: 10.1007/s00277-009-0741-7. Epub 2009 Apr 8.

PMID:
19352660
37.

HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative disease.

Andrikovics H, Meggyesi N, Szilvasi A, Tamaska J, Halm G, Lueff S, Nahajevszky S, Egyed M, Varkonyi J, Mikala G, Sipos A, Kalasz L, Masszi T, Tordai A.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):929-34. doi: 10.1158/1055-9965.EPI-08-0359. Epub 2009 Mar 3.

38.

Crystal-storing histiocytosis associated with only one of two consecutive, but genetically unrelated B-cell lymphomas.

László R, Degrell P, Kellermayer M, Bollmann D, Egyed M, Seress L, Pajor L.

Pathol Res Pract. 2009;205(4):273-8. doi: 10.1016/j.prp.2008.10.007. Epub 2008 Dec 21. Erratum in: Pathol Res Pract. 2010 Feb 15;206(2):143. Seres, László [corrected to Seress, László].

PMID:
19106020
39.

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.

Ludwig H, Hajek R, Tóthová E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A.

Blood. 2009 Apr 9;113(15):3435-42. doi: 10.1182/blood-2008-07-169565. Epub 2008 Oct 27.

40.

[Imatinib therapy in chronic myeloid leukemia].

Egyed M, Kollár B, Rajnics P, Karádi E, Matolcsi A.

Orv Hetil. 2008 Aug 10;149(32):1509-12. doi: 10.1556/OH.2008.28354. Hungarian.

PMID:
18672441
41.

Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma.

Csomor J, Kaszás I, Kollár B, Pajor L, Egyházi Z, Fekete S, Egyed M, Timár B.

Pathol Oncol Res. 2008 Sep;14(3):281-4. doi: 10.1007/s12253-008-9051-y. Epub 2008 May 21.

PMID:
18493873
42.

Severe hemolytic anemia and acute psychosis caused by Clostridium perfringens sepsis.

Egyed M, Rajnics P, Kollár B, Sinkó J, Zsoldos E, Repa I.

Med Sci Monit. 2008 Mar;14(3):CS13-6.

PMID:
18301361
43.

[Complex analysis of prognostic factors in chronic lymphocytic leukemia].

Kajtár B, Jáksó P, Kereskai L, Lacza A, Méhes G, Bodnár MA, Dombi JP, Gasztonyi Z, Egyed M, Iványi JL, Kovács G, Marton E, Palaczki A, Petz S, Tóth P, Sziládi E, Losonczy H, Pajor L.

Orv Hetil. 2007 Apr 22;148(16):737-43. Hungarian.

PMID:
17437950
44.

Successful treatment of a primary uterine B-cell lymphoma with rituximab-CHOP immunochemotherapy.

Egyed M, Kollár B, Prievara FT, Viski A, Bajzik G, Pajor L, Torday L.

Haematologica. 2007 Feb;92(2):e26-7.

45.

[Neutropenia and sepsis in hematologic patients].

Egyed M, Kollár B, Karádi E, Rajnics P, Kocsondi L, Rumi G.

Orv Hetil. 2006 Oct 22;147(42):2031-3. Hungarian.

PMID:
17165603
46.

[Cytogenetic and molecular monitoring of chronic myeloid leukemia].

Kajtár B, Méhes G, Jaksó P, Kereskai L, Iványi JL, Losonczy H, Egyed M, Tóth P, Tóth A, Gasztonyi Z, Dömötör M, Pajor L.

Orv Hetil. 2006 May 28;147(21):963-70. Review. Hungarian.

PMID:
16812971
47.

Increased incidence of monoclonal B-cell infiltrate in chronic myeloproliferative disorders.

Pajor L, Lacza A, Kereskai L, Jáksó P, Egyed M, Iványi JL, Radványi G, Dombi P, Pál K, Losonczy H.

Mod Pathol. 2004 Dec;17(12):1521-30.

48.

An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis.

Oude Lashof AM, De Bock R, Herbrecht R, de Pauw BE, Krcmery V, Aoun M, Akova M, Cohen J, Siffnerová H, Egyed M, Ellis M, Marinus A, Sylvester R, Kullberg BJ; EORTC Invasive Fungal Infections Group.

Eur J Cancer. 2004 Jun;40(9):1314-9.

PMID:
15177489
49.

Effect of retinoic acid treatment on cytogenetic remission of chronic myeloid leukaemia.

Egyed M, Kollár B, Rumi G, Keller E, Vass J, Fekete S.

Acta Haematol. 2003;109(2):84-9.

PMID:
12624492
50.

[Effect of retinoic acid on the cytogenetic remission in the first chronic phase of chronic myeloid leukemia treated with interferon].

Egyed M, Mihályfalvi Z, Kollár B, Rumi G, Keller E, Vass J, Fekete S.

Orv Hetil. 2001 Nov 4;142(44):2421-5. Hungarian.

PMID:
11766235

Supplemental Content

Support Center